Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR - Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval - Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially...